Published in Cancer Gene Ther on March 01, 2004
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res (2012) 1.01
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol (2006) 0.97
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol (2007) 0.95
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. J Immunol (2009) 0.91
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer (2016) 0.90
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol (2013) 0.89
Tumor necrosis factor receptor subfamily 9 (Tnfrsf9) gene is expressed in distinct cell populations in mouse uterus and conceptus during implantation period of pregnancy. Cell Tissue Res (2011) 0.84
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother (2008) 0.83
Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo. Cell Mol Immunol (2010) 0.81
HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism. PLoS Pathog (2015) 0.80
Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL. J Biomed Sci (2013) 0.80
Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharm Biotechnol (2013) 0.78
Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy (2009) 0.77
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77
Advances in immunotherapy for melanoma management. Hum Vaccin Immunother (2016) 0.75
T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model. Oncol Lett (2017) 0.75
The role of checkpoints in the treatment of GBM. J Neurooncol (2015) 0.75
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood (2007) 2.37
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood (2009) 2.11
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol (2009) 2.04
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood (2008) 2.00
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol (2013) 1.87
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood (2007) 1.80
Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood (2008) 1.78
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol (2009) 1.74
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant (2012) 1.65
Rituximab therapy for the type B syndrome of severe insulin resistance. N Engl J Med (2004) 1.62
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood (2011) 1.59
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood (2013) 1.59
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology (2006) 1.51
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol (2010) 1.50
Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol (2007) 1.49
Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndrome. Oncogene (2002) 1.47
Applying synthetic lethality for the selective targeting of cancer. N Engl J Med (2014) 1.44
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol (2012) 1.40
Anti-tumor immunity in a model of acute myeloid leukemia. Leuk Lymphoma (2009) 1.39
Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res (2007) 1.36
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood (2012) 1.33
Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res (2008) 1.32
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res (2006) 1.31
Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res (2002) 1.30
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol (2009) 1.30
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol (2010) 1.26
Commitment point during G0-->G1 that controls entry into the cell cycle. Mol Cell Biol (2003) 1.21
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol (2008) 1.20
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood (2012) 1.20
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res (2010) 1.19
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? Haematologica (2009) 1.18
Functional characterization of CD4+ T cells in aplastic anemia. Blood (2011) 1.17
Morphological evaluation of monocytes and their precursors. Haematologica (2009) 1.13
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol (2005) 1.11
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica (2013) 1.11
Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab (2008) 1.10
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood (2007) 1.09
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood (2002) 1.09
Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl (2005) 1.08
Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res (2003) 1.07
Life-threatening motor neurotoxicity in association with bortezomib. Haematologica (2006) 1.07
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 1.03
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol (2010) 1.02
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res (2007) 1.02
Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells. Oncogene (2003) 0.99
Epigenetics of human T cells during the G0-->G1 transition. Genome Res (2009) 0.99
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica (2009) 0.99
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol (2013) 0.97
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol (2008) 0.96
SnapShot: Acute myeloid leukemia. Cancer Cell (2012) 0.96
Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: report of three cases and review of literature. Leuk Lymphoma (2007) 0.96
Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood (2013) 0.95
Van-den Berghe's 5q- syndrome in 2008. Br J Haematol (2008) 0.93
Sarcoidosis and haematological malignancies: is there an association? Br J Haematol (2008) 0.93
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol (2006) 0.92
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica (2009) 0.92
Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol (2003) 0.92
Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun (2005) 0.90
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica (2013) 0.90
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma (2012) 0.90
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica (2012) 0.89
Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun (2005) 0.89
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol (2009) 0.89
SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun (2007) 0.89
Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag (2006) 0.89
T-cell lymphoblastic lymphoma presenting as an intra-muscular mass. Br J Haematol (2006) 0.88
A functional assay for microRNA target identification and validation. Nucleic Acids Res (2012) 0.88
Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes (2009) 0.87
Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol (2007) 0.87
Antiapoptotic microenvironment of acute myeloid leukemia. J Immunol (2004) 0.87
AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat (2008) 0.87
Targeted therapies in myeloid leukemia. Semin Cancer Biol (2004) 0.86
Bilateral retinal vasculopathy associated with autosomal dominant dyskeratosis congenita. Eur J Ophthalmol (2013) 0.86
Eltrombopag: a stem cell cookie? Blood (2014) 0.86
Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep (2003) 0.86
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol (2013) 0.85
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol (2002) 0.85
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer (2014) 0.85
Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest (2013) 0.85
Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors. Haematologica (2008) 0.84
Haematopoietic stem cell transplantation for acquired aplastic anaemia. Curr Opin Hematol (2013) 0.83
Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. Br J Haematol (2006) 0.83
Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry. Mol Syst Biol (2012) 0.82
Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. Br J Haematol (2012) 0.81
Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother (2005) 0.81
The myelodysplastic syndromes: a matter of life or death. Acta Haematol (2004) 0.81
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience. Clin Lymphoma Myeloma Leuk (2011) 0.81